8-K filing — InspireMD, Inc. (NSPR)
Filed: 2026-08-17 AccNo: 0001493152-26-038624 Size: 441 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
InspireMD shares are trading lower after the company reported mixed Q2 financial results.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 6:25 PM
- Checked
- Aug 17, 2026, 6:25 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
InspireMD Q2 EPS $(0.17) Beats $(0.19) Estimate, Sales $1.771M Miss $2.133M Estimate
InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 34.62 percent increase over losses of $(0.26) per share from the
Read original at benzingaInspireMD Announces 30-Day Outcomes From CGUARDIANS II Clinical Trial Of CGuard Prime 80cm Implant For Use In Transcarotid Artery Revascularization Procedures
InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial
Read original at benzinga